Table 1.
Characteristics of patients with Crohn’s disease associated intestinal strictures undergoing surgical resection of the stricture.
| Variables | Patients (n = 15) |
|---|---|
| Age (in years) | 43.5 ± 3.3 |
| Female (%) | 9 (60.0) |
| Male (%) | 6 (40.0) |
| Duration of disease (in years) | 10.0 ± 2.4 |
| Clinical symptoms prior surgical resection | |
| Abdominal pain (%) | 13 (86.7) |
| Diarrhea (%) | 3 (20.0) |
| Crohn’s Disease activity index | 196.6 ± 22.8 |
| Laboratory parameters | |
| White blood cell count (1/l) | 10.7 ± 0.9 |
| C-reactive protein (mg/dl) | 3.9 ± 1.3 |
| Time from initial diagnosis to surgical resection (months) | 5.4 ± 1.2 |
| Kind of surgical resection (%) | |
| Ileocaecal resection | 9 (60.0) |
| Including right hemicolectomy | 2 (13.3) |
| (Sub-) total colectomy including ileocaecal resection | 3 (20.0) |
| Anastomotic resection after ileocaecal resection | 2 (13.3) |
| Left hemicolectomy | 1 (6.7) |
| Length of intestinal stricture (cm) | 11.2 ± 2.6 |
| Medical treatment | |
| Biologics | 6 (40.0) |
| Anti-Tumor-Necrosis-Factor-α (anti-TNF-α) | 5 (33.3) |
| Ustekinumab | 1 (6.7) |
| Immunosuppressants | 5 (33.3) |
| Azathioprine | 5 (33.3) |
| Corticosteroids | 6 (40.0) |
| Systemic | 5 (33.3) |
| Topical | 1 (6.7) |
| Mesalamine | 1 (6.7) |
| Kind of medical therapy | |
| Monotherapy | 8 (53.3) |
| Combination therapy | 5 (33.3) |
| No medical therapy | 2 (13.3) |
Arithmetic mean and standard error of mean (SEM) are reported for continuous variables, and frequencies and percentages are reported for categorical variables.